Vedolizumabe no manejo das doenças inflamatórias intestinais: um estudo multicentrico observacional brasileiro

Perin, Ramir Luan; Damião, Aderson Omar Mourão Cintra; Flores, Cristina; Ludvig, Juliano Coelho; Magro, Daniéla Oliveira; Miranda, Eron Fábio; Moraes, Antonio Carlos de; Nones, Rodrigo Bremer; Teixeira, Fábio Vieira; Zeroncio, Marco; Kotze, Paulo Gustavo.
Arq. gastroenterol ; 56(3): 312-317, July-Sept. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1038718

Documentos relacionados

  1. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
  2. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
  3. PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
  4. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
  5. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
  6. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
  7. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
  8. Clinical significance of a novel uric-acid-based biomarker in the prediction of disease activity and response to infliximab therapy in Crohn's disease.
  9. Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.
  10. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.